We attended the 8th Annual ISMPP Meeting in April 2012 in Baltimore and asked attendees and speakers What type of collaborative initiatives are currently emerging within the medical publications and pharmaceutical arena?
Regionalisation of phase IV trials because of payer differences sounds like a good thing in the short term. Improved market access, for one. But has anyone considered the longer term effects?
Interesting article in PharmaVoice in April 2012 – regarding Competitive Intelligence and Competitor Strategy. The article rightly points out that Pharma is leaving good intel on the table –by not…
Ruairi O’Donnell writes in the March 2012 issue of Pharmaceutical Market Europe that evidence matters. Of course it does. And particularly in market access activities, which is the context he…
We thought we should provide some insight to the anatomy of our medical communications project manager
The ISPOR 15th Annual European Congress Abstract Submission has opened today.
Taking place at the ICC Berlin, Germany ISPOR will be accepting abstract submissions which must be submitted through ISPOR’s online abstract system by June 26th 2012.
One of our Twitter followers @HealthEcoDigest recently blogged a podcast with the BMJ editor-in-chief Fiona Godlee and neuroscientist Professor Colin Blakemore. In the podcast, they are discussing whether a false…
heor.tv inteviewed Marilyn Dix Smith, Founding Executive Director of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and asked How was ISPOR founded and how much has it changed over the years?
heor.tv inteviewed Marilyn Dix Smith, Founding Executive Director of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and asked about its impact on patient healthcare.
heor.tv polled Mark Sculpher and Ameet Bakhai with regards to what value based pricing means to them by providing some perspective on the subject.
